Speakers for this Event:  Dr. Colin Lorimer, Senior Formulation Scientist, Almac James Hurst, Analytical Support Manager, Almac Michael Rainey, Production Manager, Almac Richard Shannon, Head of Business Development (Europe), Almac Clinical Services Sponsored by:

The cost of bringing a new drug to market today is estimated to be in the region of $1 billion - a significant investment for biopharmaceutical companies therefore making it critical from the outset to ensure superior efficacy and safety when compared to an existing commercial product.

Having examined the physiochemical properties of the API and market requirements for the drug product and decided upon a capsule dosage form for clinical trial supplies, a sponsor would also consider blinding or masking when developing their protocol design. This integral part of blinding can help remove both investigator and patient bias due to the visibility of the marketed product and can limit a potential placebo effect. Over encapsulation of tablets or capsules is one of the most extensively used processes available to sponsor companies to promote blinding.

During this interactive webinar session, speakers involved will utilise their experience in the industry to explore the various mechanisms and techniques currently available in the marketplace to promote successful clinical trial supply capsule manufacture and over-encapsulation. They will also discuss key GMP challenges that need to be overcome in order to ensure product quality and study result integrity.

View this webinar to gain insight into:

• Impact & Requirements of GMP / Annex 13
• Preparation of blinded investigational medicinal products
• Evaluation of capsule manufacturing techniques and technologies
• The importance of analytical assessment
• Real life clinical case study